Evercore ISI Reiterates “Buy” Rating for Gilead Sciences (GILD)

Share on StockTwits

Evercore ISI restated their buy rating on shares of Gilead Sciences (NASDAQ:GILD) in a research note published on Wednesday.

GILD has been the topic of several other reports. Morgan Stanley boosted their price objective on shares of Gilead Sciences from $81.00 to $85.00 and gave the stock an equal weight rating in a research note on Thursday, July 26th. Piper Jaffray Companies set a $85.00 price objective on shares of Gilead Sciences and gave the stock a buy rating in a research note on Wednesday, September 12th. Zacks Investment Research lowered shares of Gilead Sciences from a strong-buy rating to a hold rating in a research note on Tuesday, September 25th. BidaskClub upgraded shares of Gilead Sciences from a sell rating to a hold rating in a research note on Tuesday, July 10th. Finally, Raymond James lowered their price objective on shares of Gilead Sciences from $97.00 to $94.00 and set a strong-buy rating on the stock in a research note on Friday, October 26th. Thirteen analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of Buy and an average target price of $87.84.

Shares of Gilead Sciences stock traded up $1.96 during trading on Wednesday, hitting $70.14. 5,624,698 shares of the stock were exchanged, compared to its average volume of 6,832,447. The firm has a market capitalization of $93.39 billion, a PE ratio of 8.19, a P/E/G ratio of -2.80 and a beta of 1.01. Gilead Sciences has a 1-year low of $64.27 and a 1-year high of $89.54. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.47 and a quick ratio of 3.39.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.21. The company had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.44 billion. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. During the same period in the previous year, the business earned $2.27 EPS. As a group, analysts expect that Gilead Sciences will post 6.44 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 28th. Investors of record on Friday, December 14th will be paid a $0.57 dividend. The ex-dividend date of this dividend is Thursday, December 13th. This represents a $2.28 dividend on an annualized basis and a yield of 3.25%. Gilead Sciences’s dividend payout ratio (DPR) is currently 26.64%.

In related news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $74.16, for a total value of $3,708,000.00. Following the transaction, the director now owns 3,067,762 shares in the company, valued at approximately $227,505,229.92. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 1.30% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the business. Northwest Bancshares Inc. grew its position in shares of Gilead Sciences by 8.9% during the 3rd quarter. Northwest Bancshares Inc. now owns 28,816 shares of the biopharmaceutical company’s stock worth $2,224,000 after purchasing an additional 2,344 shares in the last quarter. DnB Asset Management AS lifted its holdings in shares of Gilead Sciences by 4.4% during the 2nd quarter. DnB Asset Management AS now owns 156,552 shares of the biopharmaceutical company’s stock worth $11,090,000 after acquiring an additional 6,600 shares during the period. Swedbank lifted its holdings in shares of Gilead Sciences by 103.7% during the 3rd quarter. Swedbank now owns 3,906,172 shares of the biopharmaceutical company’s stock worth $301,596,000 after acquiring an additional 1,988,987 shares during the period. Fairpointe Capital LLC bought a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $708,000. Finally, IFM Investors Pty Ltd lifted its holdings in shares of Gilead Sciences by 15.8% during the 3rd quarter. IFM Investors Pty Ltd now owns 68,466 shares of the biopharmaceutical company’s stock worth $5,286,000 after acquiring an additional 9,342 shares during the period. Hedge funds and other institutional investors own 78.23% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Story: How does inflation affect different investments?

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply